Valuation dashboard for Vera Therapeutics, Inc. (VERA) with P/E N/A, P/B 5.41, EV/EBITDA -5.6 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At $30.71 (closing price, November 3, 2026), VERA has negative trailing earnings (P/E not meaningful) and an ROE of -84.13%. Market capitalisation stands at $2.2B.
Balance sheet quality for VERA: debt-to-equity ratio of 0.18, current ratio of 10.92 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 5.41 |
| EV / EBITDA | -5.6 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| VERA | Vera Therapeutics, Inc. | $2.2B | 5.41 | -84.1% | |
| DNTH | Dianthus Therapeutics, Inc. | $4.6B | 3.95 | -3.5% | |
| ARQT | Arcutis Biotherapeutics, Inc. | $4.0B | 153.48 | 18.94 | 15.1% |
| BHVN | Biohaven Ltd. | $2.4B | -22.7% | ||
| VRTX | Vertex Pharmaceuticals Incorporated | $134.5B | 34.15 | 6.44 | 20.1% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $100.2B | 21.51 | 2.96 | 15.1% |
| MRNA | Moderna, Inc. | $91.2B | 13.38 | -39.2% |
Price
| Price | $30.71 (closing price, November 3, 2026) |
| Market Cap | $2.2B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -84.13% |
| Return on Invested Capital | -85.78% |
| Return on Assets | -75.40% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: DNTH · ARQT · BHVN · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of VERA: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks